CGON · CG Oncology, Inc. · Insider Trading

Fully vested

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.54 to $73.52 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.

Fully vested

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.

Fully vested

Fully vested.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.98 to $75.79 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The Reporting Person, as the managing member of Seven Fleet Advisors, LLC, the investment manager of Seven Fleet Partners, LP, may be deemed to beneficially own the shares of Common Stock held by Seven Fleet Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.

Fully vested

Fully vested

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.

The stock option vested in 36 substantially equal monthly installments beginning on July 14, 2023.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.

The stock option vests in 36 substantially equal monthly installments beginning on January 13, 2024.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.

1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026

The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026

Fully vested.

The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026

1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.99 to $73.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Fully vested.

1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

The stock option vests over a four-year period starting on April 15, 2026 (the "Vesting Commencement Date"), with 25% of the shares vesting on the date that is twelve months after the Vesting Commencement Date and the remainder vesting in thirty-six equal monthly installments over the subsequent three-year period.

1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

The stock option vests in 36 substantially equal monthly installments beginning on January 13, 2024.

The stock option vests in 36 substantially equal monthly installments beginning on July 14, 2023.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

Represents a "net exercise" of outstanding stock options. The reporting person received 62,765 shares of common stock on net exercise of an option to purchase 64,612 shares of common stock. The Company withheld 1,847 shares of common stock underlying the option and the reporting person paid in cash the delta for payment in full of the aggregate exercise price. This transaction does not represent a sale by the reporting person.